CM
FOLD

Castleark Management’s Amicus Therapeutics FOLD Stock Holding History

Castleark Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-260,700
Closed -$6.02M – 347
2020
Q4 		$6.02M Sell
260,700
-107,005
-29% -$2.19M 0.23% 124
2020
Q3 		$5.19M Buy
+367,705
New +$5.36M 0.2% 123
2019
Q2 		– Sell
-441,674
Closed -$6.01M – 369
2019
Q1 		$6.01M Buy
+441,674
New +$5.4M 0.23% 145

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Castleark Management's FOLD Position: Q1 2021 in Review

Castleark Management sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 260,700 shares — an estimated $6.02M sold.

Castleark Management first reported a position in FOLD in Q1 2019 and held it in 3 quarters. The position peaked at $6.02M in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

  • Castleark Management reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Castleark Management sold 260,700 Amicus Therapeutics shares in Q1 2021, an estimated $6.02M.
  • Castleark Management first reported a position in Amicus Therapeutics in Q1 2019 and held it in 3 quarters.
  • Castleark Management's Amicus Therapeutics position peaked at $6.02M in Q4 2020.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Castleark Management's 13F filing for Q1 2021, filed 14 May 2021.